TFL Gallery / t-eff-adas-wk24-completers
EFT04 · Table
ADAS-Cog (11) - Change from Baseline to Week 24 - Completers at Week 24, Observed Cases, Windowed
Week 24 restricted to subjects who completed it, observed cases only, with no value carried forward. The sensitivity analysis against the primary table's imputation.
- Slug
- t-eff-adas-wk24-completers
- Regulatory ID
- EFT04
- Type
- Table
- E3 position
- §14.2
- Status
- evidenced
- Current iteration
- v002
- Evidence
- 26/26 passing
- Requirements
- DSP-ALL-001 DSP-ALL-002 DSP-EFF-001 DSP-EFF-002 DSP-EFF-003 DSP-EFF-004 DSP-EFF-005 DSP-EFF-006 DSP-EFF-007 DSP-EFF-008 DSP-EFF-009 DSP-INTXT-001 DSP-INTXT-002 DSP-INTXT-003 STD-GATE-001 STD-GATE-002 STD-GATE-003 STD-GATE-004 STD-GATE-005 STD-MODEL-001 STD-MODEL-002 STD-MODEL-003 STD-MODEL-004 STD-MODEL-005 STD-SRC-001 STD-SRC-002
- Used in
- Clinical Study Report Table 14.2.7
- Post-Text Display Package Table 14.2.7
- Abbreviated Clinical Study Report (ICH E3) Table 14.2.7
- Study model
- Efficacy Analysis Set EFFFL · grouped by TRTP
- Specification
- 2 iterations
- Environment
- R 4.3.3 Darwin 23.6.0
- Bound by
- No text block binds it
- Values
- No value is sourced from it
- adsl254 rows · 70c7278
- adqsadas12463 rows · d6ee9a3
- analysis.yamlwhat to compute
- display.yamlhow to show it
- custom.Rthe display's own method
- study modelEfficacy Analysis Set
- prepare_data()regenerate('t-eff-adas-wk24-completers')
- build_ard()one row per statistic
- render_display()every variant
- render_rtf()the same cells
- ard.jsonv002 · 95 rows · 9c9aef7
- table.htmlthe rendered display
- table.rtfsha256 d50f930
- manifest.jsonwho, why, every hash
Generated by the same pipeline run that wrote the ARD and the HTML above, from the same rendered cells; the short hash is the manifest's record of the file.
| ADAS-Cog (11) - Change from Baseline to Week 24 - Completers at Week 24, Observed Cases, Windowed | |||
| Study CDISCPILOT01 — Efficacy Analysis Set, Week 24 completers | |||
| Placebo (N=60) | Xanomeline Low Dose (N=28) | Xanomeline High Dose (N=30) | |
|---|---|---|---|
| Baseline | |||
| n | |||
| Mean (SD) | |||
| Median (Range) | |||
| Week 24 | |||
| n | |||
| Mean (SD) | |||
| Median (Range) | |||
| Change from baseline | |||
| n | |||
| Mean (SD) | |||
| Median (Range) | |||
| Statistical comparison of the change from baseline | |||
| p-value (dose response) [1][2] | |||
| p-value (Xanomeline - Placebo) [1][3] | |||
| Difference of LS means (SE) | |||
| 95% CI | |||
| p-value (Xanomeline High - Xanomeline Low) [1][3] | |||
| Difference of LS means (SE) | |||
| 95% CI | |||
| [1] Based on an analysis of covariance (ANCOVA) model with treatment and site group as factors and the baseline score as a covariate. | |||
| [2] Test for a non-zero coefficient for treatment (dose) as a continuous variable. | |||
| [3] Pairwise comparison with treatment as a categorical variable; p-values are not adjusted for multiple comparisons. | |||
| Only assessments falling within the Week 24 assessment window are included, and no value is imputed. | |||
| Baseline, on-treatment and change statistics are summarised over one record per subject at the analysis visit, so a subject with no assessment in that window contributes to none of the three and n is smaller than the column N. | |||
| Treatment columns are planned treatment (TRTP), which is how the CDISCPILOT01 reference report presents them. | |||
| CDISCPILOT01 states no data cut-off date. The date shown is the latest ADAS-Cog assessment date present in the vendored ADaM package. | |||
| Source: adqsadas (ADAS-Cog (11) total score, PARAMCD ACTOT) and adsl, from the CDISC pilot's own ADaM package (phuse-org/phuse-scripts, MIT). Analysis as specified in the CDISCPILOT01 statistical analysis plan, section 10.1.1. Reference report display: Table 14-3.07. Data cut-off: 2015-02-17. | |||
| open.csr display t-eff-adas-wk24-completers (post_text variant); generated from the committed ARD. | |||
Rendered from outputs/t-eff-adas-wk24-completers/v002/table.html.
| analysis | group1 | group1_level | group2 | group2_level | variable | variable_level | context | stat_name | stat_label | warning | error | stat |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| population | TRTP | Placebo | — | — | USUBJID | — | population | N | N | — | — | 60 |
| population | TRTP | Xanomeline High Dose | — | — | USUBJID | — | population | N | N | — | — | 30 |
| population | TRTP | Xanomeline Low Dose | — | — | USUBJID | — | population | N | N | — | — | 28 |
| summary | TRTP | Placebo | — | — | BASE | — | continuous | N | N | — | — | 59 |
| summary | TRTP | Placebo | — | — | BASE | — | continuous | mean | Mean | — | — | 23.1969608416131 |
| summary | TRTP | Placebo | — | — | BASE | — | continuous | sd | SD | — | — | 11.7412602305514 |
| summary | TRTP | Placebo | — | — | BASE | — | continuous | median | Median | — | — | 21 |
| summary | TRTP | Placebo | — | — | BASE | — | continuous | p25 | Q1 | — | — | 15 |
| summary | TRTP | Placebo | — | — | BASE | — | continuous | p75 | Q3 | — | — | 29 |
| summary | TRTP | Placebo | — | — | BASE | — | continuous | min | Min | — | — | 5 |
| summary | TRTP | Placebo | — | — | BASE | — | continuous | max | Max | — | — | 51 |
| summary | TRTP | Placebo | — | — | AVAL | — | continuous | N | N | — | — | 59 |
| summary | TRTP | Placebo | — | — | AVAL | — | continuous | mean | Mean | — | — | 25.2559906487434 |
| summary | TRTP | Placebo | — | — | AVAL | — | continuous | sd | SD | — | — | 13.3155008456192 |
| summary | TRTP | Placebo | — | — | AVAL | — | continuous | median | Median | — | — | 23 |
| summary | TRTP | Placebo | — | — | AVAL | — | continuous | p25 | Q1 | — | — | 16 |
| summary | TRTP | Placebo | — | — | AVAL | — | continuous | p75 | Q3 | — | — | 31 |
| summary | TRTP | Placebo | — | — | AVAL | — | continuous | min | Min | — | — | 5 |
| summary | TRTP | Placebo | — | — | AVAL | — | continuous | max | Max | — | — | 58 |
| summary | TRTP | Placebo | — | — | CHG | — | continuous | N | N | — | — | 59 |
| summary | TRTP | Placebo | — | — | CHG | — | continuous | mean | Mean | — | — | 2.05902980713033 |
| summary | TRTP | Placebo | — | — | CHG | — | continuous | sd | SD | — | — | 5.88919042785207 |
| summary | TRTP | Placebo | — | — | CHG | — | continuous | median | Median | — | — | 2 |
| summary | TRTP | Placebo | — | — | CHG | — | continuous | p25 | Q1 | — | — | -1 |
| summary | TRTP | Placebo | — | — | CHG | — | continuous | p75 | Q3 | — | — | 6 |
| summary | TRTP | Placebo | — | — | CHG | — | continuous | min | Min | — | — | -11 |
| summary | TRTP | Placebo | — | — | CHG | — | continuous | max | Max | — | — | 16 |
| summary | TRTP | Xanomeline High Dose | — | — | BASE | — | continuous | N | N | — | — | 30 |
| summary | TRTP | Xanomeline High Dose | — | — | BASE | — | continuous | mean | Mean | — | — | 20.5333333333333 |
| summary | TRTP | Xanomeline High Dose | — | — | BASE | — | continuous | sd | SD | — | — | 11.5033228582705 |
| summary | TRTP | Xanomeline High Dose | — | — | BASE | — | continuous | median | Median | — | — | 18 |
| summary | TRTP | Xanomeline High Dose | — | — | BASE | — | continuous | p25 | Q1 | — | — | 11 |
| summary | TRTP | Xanomeline High Dose | — | — | BASE | — | continuous | p75 | Q3 | — | — | 26 |
| summary | TRTP | Xanomeline High Dose | — | — | BASE | — | continuous | min | Min | — | — | 3 |
| summary | TRTP | Xanomeline High Dose | — | — | BASE | — | continuous | max | Max | — | — | 49 |
| summary | TRTP | Xanomeline High Dose | — | — | AVAL | — | continuous | N | N | — | — | 30 |
| summary | TRTP | Xanomeline High Dose | — | — | AVAL | — | continuous | mean | Mean | — | — | 21.8080459770115 |
| summary | TRTP | Xanomeline High Dose | — | — | AVAL | — | continuous | sd | SD | — | — | 12.6007772693716 |
| summary | TRTP | Xanomeline High Dose | — | — | AVAL | — | continuous | median | Median | — | — | 18.5 |
| summary | TRTP | Xanomeline High Dose | — | — | AVAL | — | continuous | p25 | Q1 | — | — | 11 |
| summary | TRTP | Xanomeline High Dose | — | — | AVAL | — | continuous | p75 | Q3 | — | — | 34 |
| summary | TRTP | Xanomeline High Dose | — | — | AVAL | — | continuous | min | Min | — | — | 3 |
| summary | TRTP | Xanomeline High Dose | — | — | AVAL | — | continuous | max | Max | — | — | 44 |
| summary | TRTP | Xanomeline High Dose | — | — | CHG | — | continuous | N | N | — | — | 30 |
| summary | TRTP | Xanomeline High Dose | — | — | CHG | — | continuous | mean | Mean | — | — | 1.27471264367816 |
| summary | TRTP | Xanomeline High Dose | — | — | CHG | — | continuous | sd | SD | — | — | 4.51026485921586 |
| summary | TRTP | Xanomeline High Dose | — | — | CHG | — | continuous | median | Median | — | — | 1 |
| summary | TRTP | Xanomeline High Dose | — | — | CHG | — | continuous | p25 | Q1 | — | — | -2 |
| summary | TRTP | Xanomeline High Dose | — | — | CHG | — | continuous | p75 | Q3 | — | — | 4 |
| summary | TRTP | Xanomeline High Dose | — | — | CHG | — | continuous | min | Min | — | — | -6.75862068965517 |
| summary | TRTP | Xanomeline High Dose | — | — | CHG | — | continuous | max | Max | — | — | 13 |
| summary | TRTP | Xanomeline Low Dose | — | — | BASE | — | continuous | N | N | — | — | 27 |
| summary | TRTP | Xanomeline Low Dose | — | — | BASE | — | continuous | mean | Mean | — | — | 24.0063856960409 |
| summary | TRTP | Xanomeline Low Dose | — | — | BASE | — | continuous | sd | SD | — | — | 13.8856643512354 |
| summary | TRTP | Xanomeline Low Dose | — | — | BASE | — | continuous | median | Median | — | — | 20 |
| summary | TRTP | Xanomeline Low Dose | — | — | BASE | — | continuous | p25 | Q1 | — | — | 14 |
| summary | TRTP | Xanomeline Low Dose | — | — | BASE | — | continuous | p75 | Q3 | — | — | 30 |
| summary | TRTP | Xanomeline Low Dose | — | — | BASE | — | continuous | min | Min | — | — | 5 |
| summary | TRTP | Xanomeline Low Dose | — | — | BASE | — | continuous | max | Max | — | — | 56.7241379310345 |
| summary | TRTP | Xanomeline Low Dose | — | — | AVAL | — | continuous | N | N | — | — | 27 |
| summary | TRTP | Xanomeline Low Dose | — | — | AVAL | — | continuous | mean | Mean | — | — | 24.0689655172414 |
| summary | TRTP | Xanomeline Low Dose | — | — | AVAL | — | continuous | sd | SD | — | — | 11.8740532268791 |
| summary | TRTP | Xanomeline Low Dose | — | — | AVAL | — | continuous | median | Median | — | — | 22 |
| summary | TRTP | Xanomeline Low Dose | — | — | AVAL | — | continuous | p25 | Q1 | — | — | 15 |
| summary | TRTP | Xanomeline Low Dose | — | — | AVAL | — | continuous | p75 | Q3 | — | — | 32 |
| summary | TRTP | Xanomeline Low Dose | — | — | AVAL | — | continuous | min | Min | — | — | 8 |
| summary | TRTP | Xanomeline Low Dose | — | — | AVAL | — | continuous | max | Max | — | — | 51 |
| summary | TRTP | Xanomeline Low Dose | — | — | CHG | — | continuous | N | N | — | — | 27 |
| summary | TRTP | Xanomeline Low Dose | — | — | CHG | — | continuous | mean | Mean | — | — | 0.0625798212005104 |
| summary | TRTP | Xanomeline Low Dose | — | — | CHG | — | continuous | sd | SD | — | — | 5.86215507065048 |
| summary | TRTP | Xanomeline Low Dose | — | — | CHG | — | continuous | median | Median | — | — | 1 |
| summary | TRTP | Xanomeline Low Dose | — | — | CHG | — | continuous | p25 | Q1 | — | — | -5 |
| summary | TRTP | Xanomeline Low Dose | — | — | CHG | — | continuous | p75 | Q3 | — | — | 3 |
| summary | TRTP | Xanomeline Low Dose | — | — | CHG | — | continuous | min | Min | — | — | -11 |
| summary | TRTP | Xanomeline Low Dose | — | — | CHG | — | continuous | max | Max | — | — | 12 |
| ancova | TRTP | Xanomeline High Dose | — | — | CHG | dose_response | ancova | pvalue | pvalue | — | — | 0.2343441504705 |
| ancova | TRTP | Xanomeline High Dose | — | — | CHG | dose_response | ancova | n_model | n_model | — | — | 116 |
| ancova | TRTP | Xanomeline Low Dose | — | — | CHG | xan_vs_placebo | ancova | estimate | estimate | — | — | -2.06524913382622 |
| ancova | TRTP | Xanomeline Low Dose | — | — | CHG | xan_vs_placebo | ancova | se | se | — | — | 1.26417635297979 |
| ancova | TRTP | Xanomeline Low Dose | — | — | CHG | xan_vs_placebo | ancova | pvalue | pvalue | — | — | 0.105410836110464 |
| ancova | TRTP | Xanomeline Low Dose | — | — | CHG | xan_vs_placebo | ancova | lcl | lcl | — | — | -4.57273693594894 |
| ancova | TRTP | Xanomeline Low Dose | — | — | CHG | xan_vs_placebo | ancova | ucl | ucl | — | — | 0.442238668296504 |
| ancova | TRTP | Xanomeline Low Dose | — | — | CHG | xan_vs_placebo | ancova | n_model | n_model | — | — | 116 |
| ancova | TRTP | Xanomeline High Dose | — | — | CHG | xan_vs_placebo | ancova | estimate | estimate | — | — | -0.900505625695855 |
| ancova | TRTP | Xanomeline High Dose | — | — | CHG | xan_vs_placebo | ancova | se | se | — | — | 1.21607624885566 |
| ancova | TRTP | Xanomeline High Dose | — | — | CHG | xan_vs_placebo | ancova | pvalue | pvalue | — | — | 0.460697277382587 |
| ancova | TRTP | Xanomeline High Dose | — | — | CHG | xan_vs_placebo | ancova | lcl | lcl | — | — | -3.31258709935199 |
| ancova | TRTP | Xanomeline High Dose | — | — | CHG | xan_vs_placebo | ancova | ucl | ucl | — | — | 1.51157584796028 |
| ancova | TRTP | Xanomeline High Dose | — | — | CHG | xan_vs_placebo | ancova | n_model | n_model | — | — | 116 |
| ancova | TRTP | Xanomeline High Dose | — | — | CHG | high_vs_low | ancova | estimate | estimate | — | — | 1.16474350813036 |
| ancova | TRTP | Xanomeline High Dose | — | — | CHG | high_vs_low | ancova | se | se | — | — | 1.47020793386968 |
| ancova | TRTP | Xanomeline High Dose | — | — | CHG | high_vs_low | ancova | pvalue | pvalue | — | — | 0.430064989693755 |
| ancova | TRTP | Xanomeline High Dose | — | — | CHG | high_vs_low | ancova | lcl | lcl | — | — | -1.75140695780167 |
| ancova | TRTP | Xanomeline High Dose | — | — | CHG | high_vs_low | ancova | ucl | ucl | — | — | 4.0808939740624 |
| ancova | TRTP | Xanomeline High Dose | — | — | CHG | high_vs_low | ancova | n_model | n_model | — | — | 116 |
95 rows, one per computed statistic.
- Schema
- opencsr/ard/v1
- Generated
- 2026-09-02T15:23:24Z
- Spec hash
- sha256:09b745393b790b3d3fe47b5fa5dc6172d368d476e5a89e02dfb03d668c83cbeb
- Display hash
- sha256:4cf74d8b96155eb9b2da498fa61cb953216d457fa0ccacec5aecfe19a77cebcf
- ARD file
- outputs/t-eff-adas-wk24-completers/v002/ard.json
- ARD hash
- sha256:9c9aef70416902d5e01cb7492d4c9969b7c0b9e8c0638f96226494c85d75a85b
Source datasets
| Dataset | Rows | Package | Hash |
|---|---|---|---|
| adsl | 254 | phuse-org/phuse-scripts:data/adam 398a6d33ced9359ffb58c46650a6d488811176b1 | sha256:70c7278e83e571a7d4a94fd864c98bf8ca243c7c2cc9eec8b99a40fa7bc98e35 |
| adqsadas | 12463 | phuse-org/phuse-scripts:data/adam 398a6d33ced9359ffb58c46650a6d488811176b1 | sha256:d6ee9a321a2a9d338285cc702d750624eefd6da11b0da0ae260a4133a492215f |
Environment
R 4.3.3 · Darwin 23.6.0 · cards 0.6.1 · cardx 0.2.5 · gtsummary 2.3.0 · gt 1.0.0 · dplyr 1.1.4 · pharmaverseadam 1.1.0 · jsonlite 2.0.0 · yaml 2.3.10 · digest 0.6.37
id: t-eff-adas-wk24-completers
title: "ADAS-Cog (11) - Change from Baseline to Week 24 - Completers at Week 24, Observed Cases, Windowed"
regulatory_id: EFT04
type: table
dataset: adqsadas
analysis_set: efficacy
denominator: adsl
sources: phuse
group:
- TRTP
total: false
analyses:
- name: population
method: continuous
custom: population_n
label: "Subjects in the analysis population"
filter: "PARAMCD == 'ACTOT' & COMP24FL == 'Y'"
- name: summary
method: continuous
label: "ADAS-Cog (11) total score at baseline, at Week 24, and its change"
variables: [BASE, AVAL, CHG]
filter: "PARAMCD == 'ACTOT' & ANL01FL == 'Y' & COMP24FL == 'Y' & !(DTYPE %in% 'LOCF') & AVISIT == 'Week 24'"
- name: ancova
method: continuous
custom: ancova_change
label: "ANCOVA of the change from baseline to Week 24"
variables: [CHG]
filter: "PARAMCD == 'ACTOT' & ANL01FL == 'Y' & COMP24FL == 'Y' & !(DTYPE %in% 'LOCF') & AVISIT == 'Week 24'"
response: CHG
covariates: [BASE]
factors: [SITEGR1]
treatment: TRTP
treatment_levels: ["Placebo", "Xanomeline Low Dose", "Xanomeline High Dose"]
dose: TRTPN
conf_level: 0.95
contrasts:
- { name: dose_response, type: dose, column: "Xanomeline High Dose" }
- { name: xan_vs_placebo, type: pairwise, test: "Xanomeline Low Dose",
reference: "Placebo", column: "Xanomeline Low Dose" }
- { name: xan_vs_placebo, type: pairwise, test: "Xanomeline High Dose",
reference: "Placebo", column: "Xanomeline High Dose" }
- { name: high_vs_low, type: pairwise, test: "Xanomeline High Dose",
reference: "Xanomeline Low Dose", column: "Xanomeline High Dose" }
id: t-eff-adas-wk24-completers
title: "ADAS-Cog (11) - Change from Baseline to Week 24 - Completers at Week 24, Observed Cases, Windowed"
study: CDISCPILOT01
population_label: "Efficacy Analysis Set, Week 24 completers"
cutoff: "2015-02-17"
source: "Source: adqsadas (ADAS-Cog (11) total score, PARAMCD ACTOT) and adsl, from the CDISC pilot's own ADaM package (phuse-org/phuse-scripts, MIT). Analysis as specified in the CDISCPILOT01 statistical analysis plan, section 10.1.1. Reference report display: Table 14-3.07. Data cut-off: 2015-02-17."
footnotes:
- "[1] Based on an analysis of covariance (ANCOVA) model with treatment and site group as factors and the baseline score as a covariate."
- "[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable."
- "[3] Pairwise comparison with treatment as a categorical variable; p-values are not adjusted for multiple comparisons."
- "Only assessments falling within the Week 24 assessment window are included, and no value is imputed."
- "Baseline, on-treatment and change statistics are summarised over one record per subject at the analysis visit, so a subject with no assessment in that window contributes to none of the three and n is smaller than the column N."
- "Treatment columns are planned treatment (TRTP), which is how the CDISCPILOT01 reference report presents them."
- "CDISCPILOT01 states no data cut-off date. The date shown is the latest ADAS-Cog assessment date present in the vendored ADaM package."
columns:
order: ["Placebo", "Xanomeline Low Dose", "Xanomeline High Dose"]
format:
mean_sd: "{mean} ({sd})"
median_range: "{median} ({min};{max})"
est_se: "{estimate} ({se})"
ci: "({lcl};{ucl})"
p_value: "{pvalue}"
digits:
mean: 1
sd: 2
median: 1
min: 0
max: 0
estimate: 1
se: 2
lcl: 1
ucl: 1
pvalue: 3
rows:
- { label: "Baseline", section: true }
- { analysis: summary, variable: BASE, pattern: "N", label: "n", indent: 1 }
- { analysis: summary, variable: BASE, pattern: mean_sd, label: "Mean (SD)", indent: 1 }
- { analysis: summary, variable: BASE, pattern: median_range, label: "Median (Range)", indent: 1 }
- { label: "Week 24", section: true }
- { analysis: summary, variable: AVAL, pattern: "N", label: "n", indent: 1 }
- { analysis: summary, variable: AVAL, pattern: mean_sd, label: "Mean (SD)", indent: 1 }
- { analysis: summary, variable: AVAL, pattern: median_range, label: "Median (Range)", indent: 1 }
- { label: "Change from baseline", section: true }
- { analysis: summary, variable: CHG, pattern: "N", label: "n", indent: 1 }
- { analysis: summary, variable: CHG, pattern: mean_sd, label: "Mean (SD)", indent: 1 }
- { analysis: summary, variable: CHG, pattern: median_range, label: "Median (Range)", indent: 1 }
- { label: "Statistical comparison of the change from baseline", section: true }
- { analysis: ancova, variable: CHG, level: dose_response, pattern: p_value,
label: "p-value (dose response) [1][2]", indent: 1 }
- { analysis: ancova, variable: CHG, level: xan_vs_placebo, pattern: p_value,
label: "p-value (Xanomeline - Placebo) [1][3]", indent: 1 }
- { analysis: ancova, variable: CHG, level: xan_vs_placebo, pattern: est_se,
label: "Difference of LS means (SE)", indent: 2 }
- { analysis: ancova, variable: CHG, level: xan_vs_placebo, pattern: ci,
label: "95% CI", indent: 2 }
- { analysis: ancova, variable: CHG, level: high_vs_low, pattern: p_value,
label: "p-value (Xanomeline High - Xanomeline Low) [1][3]", indent: 1 }
- { analysis: ancova, variable: CHG, level: high_vs_low, pattern: est_se,
label: "Difference of LS means (SE)", indent: 2 }
- { analysis: ancova, variable: CHG, level: high_vs_low, pattern: ci,
label: "95% CI", indent: 2 }
variants:
post_text: {}
# Display-specific statistics (contract section 2).
#
# Both functions are thin wrappers: the statistics themselves live in
# {opencsr} so that the seven ADAS-Cog displays share one tested
# implementation, and every model term is declared in this display's
# analysis.yaml rather than written in code.
ancova_change <- function(data, spec, denominator = NULL) {
opencsr::ard_ancova(data, spec, denominator)
}
population_n <- function(data, spec, denominator = NULL) {
opencsr::ard_population_n(data, spec, denominator)
}
v002current
One study (D0032 R2, #59): regenerated so the ARD carries its population record for the treatment-consistency gate. Spec and lane unchanged; every statistic identical.
2026-09-02T15:23:24Z · @obotclaw
v001
Complete the preserved specification: first generation of numbers and rendered output.
2026-08-27T03:41:22Z · obot worker W0137
Every iteration is kept: outputs/t-eff-adas-wk24-completers/vNNN/ holds the spec snapshot, the ARD, the rendered output, and a manifest recording who regenerated it, why, and from which commit.